Molecular Haemato-oncology

If you have chosen to participate in any Molecular Haemato-oncology EQA programme except Chimerism you will receive a lyophilised cell-line/patient sample preparation for molecular analysis. Instructions for storage, reconstitution and use of the lyophilised sample will be included with the sample. Prior to reconstitution, the lyophilised cells are stable at ambient temperature however, once the cells are reconstituted they should be processed immediately.

Please note- all lyophilised samples provided within these programmes are for EQA purposes only.

If you have chosen to participate in the Chimerism programme (and in some circumstances Ig/TCR clonality trials) you will currently receive fresh blood samples. Upon receipt, these samples should be processed immediately to prevent any degradation of the DNA.

***New for 2026-2027***

As part of the continuous development of our EQA/PT provision we will be introducing several updates to our molecular haemato-oncology programmes in 2024-2025.

Extending Accreditation for the Myeloproliferative Neoplasms Diagnostic  Testing programme 
Following the successful consolidation of the JAK2 p.Val617Phe) Mutation Status and the Myeloproliferative Neoplasms Diagnostic Testing programmes in the 2024-2025 registration period we will be applying to extend accreditation beyond qualitative JAK2 V617F testing. This will include the remaining three core MPN markers (JAK2 exon 12, CALR exon 9 and MPL exon 10 variants) as well as quantitative testing of JAK2 V617F. Please note that testing for all markers will not be mandatory; participants are required to submit results only for assays provided by their laboratory. 
 

Pilot Liquid Biopsy in DLBCL EQA Study

UK NEQAS LI hope to run a small pilot study assessing the use of next generation sequencing based liquid biopsy testing in diffuse large B cell lymphoma, if there is sufficient interest. Please contact us if you wish to be part of this study (admin@ukneqasli.co.uk). 

Minor Programme Changes 

In 2026-2027, we will be making several minor changes to the molecular haemato-oncology programmes, to include: automating data analysis and reporting in the Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinaemia programme; improvement of the data entry page to capture digital PCR/Cepheid data in the BCR::ABL1 Minor Quantification programme. 

Webinar Plans 

We will be hosting a webinar in March 2026. This will focus on how leukaemia diagnosis is changing in the light of greater scientific understanding and technological advances. We will discuss how the UK NEQAS LI programmes are evolving to support this.

Please see programme specific pages on our website for further details.

* denotes changes to the programme in 2026/2027